FDA warns of recalled compounded drugs in Michigan

October 22, 2013

The Food and Drug Administration is warning doctors, veterinarians and patients to avoid certain sterile drugs distributed by the Specialty Medicine Compounding Pharmacy of Michigan.

The pharmacy, in South Lyon near Detroit, has recalled drugs distributed in Michigan between July 1 and Oct. 19. The company says no drugs were distributed outside the state.

The specialty pharmacy agreed to conduct the recall after finding floating particles in a sterile that came from a lot that may have been given to hospital patients. The FDA says it's unclear what the particles were.

The FDA recommends doctors and stop using drugs from the pharmacy immediately. For additional details, the public can contact the Specialty Medicine Compounding Pharmacy at 248-446-2643.

No have been reported in connection with the recall.

Explore further: FDA warns of infections tied to Tennessee pharmacy

Related Stories

FDA warns of infections tied to Tennessee pharmacy

May 24, 2013
(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.

FDA: Georgia pharmacy recalling all sterile drugs

March 21, 2013
(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Indianapolis pharmacy recalls compounded drugs

April 23, 2013
(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Fla. compounding pharmacy recalls sterile drugs

April 21, 2013
A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

US warns of mold in recalled specialty drugs

March 18, 2013
The U.S. Food and Drug Administration warned doctors and hospital managers Monday about a nationwide recall of all drugs made by a New Jersey compounding pharmacy because of possible mold contamination.

FDA warns of another compounding pharmacy recall

March 20, 2013
(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.